Management of osteoporosis and menopausal symptoms: Focus on bazedoxifene/conjugated estrogen combination

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 465-475

  Mirkin, Sebastian ^a   Pickar, James H ^b  

^a PFIZER INC   (United States)

^b Department of Medicine   (United States)

Author keywords

Bazedoxifene; Conjugated estrogens; Menopause; Osteoporosis; Tissue selective estrogen complex; Vasomotor symptoms

Indexed keywords

BAZEDOXIFENE; CONJUGATED ESTROGEN; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PLACEBO; RALOXIFENE;

AMENORRHEA; BONE DENSITY; BREAST CANCER; BREAST TENDERNESS; CEREBROVASCULAR DISEASE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HORMONAL THERAPY; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; MASTALGIA; MENOPAUSAL SYNDROME; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VAGINA ATROPHY; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM;

EID: 84881269088     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S39455     Document Type: Review

References (28)

1. Archer DF. Tissue-selective estrogen complexes: a promising option for the comprehensive management of menopausal symptoms. Drugs Aging. 2010;27:533-544.
2. Maartens LW, Leusink GL, Knottnerus JA, et al. Climacteric complaints in the community. Fam Pract. 2001;18:189-194.
3. Lewis V. Undertreatment of menopausal symptoms and novel options for comprehensive management. Curr Med Res Opin. 2009;25: 2689-2698.
4. Geukes M, Van Aalst M P, Nauta MCE, et al. The impact of menopausal symptoms on work ability. Menopause. 2012;19:278-282.
5. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000;152:463-473.
6. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96: 351-358.
7. Al-Azzawi F, Habiba M. Regular bleeding on hormone replacement therapy: a myth? Br J Obstet Gynaecol. 1994;101:661-662.
8. Limouzin-Lamothe MA. What women want from hormone replacement therapy: results of an international survey. Eur J Obstet Gynecol Reprod Biol. 1996;64 Suppl:S21-S24.
9. Pfzer Pharmaceuticals Inc. PremPro package insert. Available from: http://labeling.pfizer.com/showlabeling.aspx?id=133. Accessed October 11, 2011.
10. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogen-progestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol. 1997;15:3201-3207.
11. Lee E, Ingles SA, Berg VD, et al. Progestogen levels, progesterone receptor gene polymorphisms, and mammographic density changes: results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. Menopause. 2012;19:302-310.
12. Brower V. Homing in on mechanisms linking breast density to breast cancer risk. J Natl Cancer Inst. 2010;102:843-845.
13. Kerlikowske K, Cook AJ, Buist DSM. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J Clin Oncol. 2010;28:3830-3837.
14. Crandall CJ, Aragaki AK, Cauley JA, et al. Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. Breast Cancer Res Treat. 2012; 132:275-285.
15. Haas JS, Kaplan C P, Gerstenberger E P, Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med. 2004;140:184-188.
16. Komm B. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008;15:984-992.
17. Lobo RA, Pinkerton J V, Gass ML, et al. Evaluation of bazedoxifene/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profle. Fertil Steril. 2009;92:1025-1038.
18. Pinkerton J V, Utian WH, Constantine GD, Olivier S, Pickar JH. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16:1116-1124.
19. Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause. 2010;17:281-289.
20. Pinkerton J V, Taylor H, Pan K, Chines A, Mirkin S. Breast parameters with bazedoxifene/conjugated estrogens in randomized, controlled trials of postmenopausal women. Menopause. 2010;17:1221-1222.
21. MacLennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot fushes. Cochrane Database Syst Rev. 2004;4:CD002978.
22. Utian W, Yu H, Bobula J, Mirkin S, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens and quality of life in postmenopausal women. Maturitas. 2009;63:329-335.
23. De Villiers TJ. Bazedoxifene: a novel selective estrogen receptor modulator for postmenopausal osteoporosis. Climacteric. 2010;13:210-218.
24. Pickar JH, Ye h I-T, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/ conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92: 1018-1024.
25. Archer DF, Lewis V, Carr BR, Olivier S, Pickar JH. Bazedoxifene/ conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril. 2009;92:1039-1044.
26. Chlebowski RT, Hendrix SL, Langer RD, et al. Infuence of estrogen plus progestin on breast cancer and mammography in healthy post-menopausal women. JAMA. 2003;289:3234-3253.
27. Pfzer Pharmaceuticals Inc. Premarin US Package Insert. Available from: http://labeling.pfzer.com/showlabeling.aspx?id=131. Accessed December 13, 2011.
28. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001;76:13-24.